New Delivery Tech Targets siRNA to Breast Cancer Cells to Suppress HER2-Positive Tumor Growth | GenomeWeb

An international team of researchers this month reported on the development of a targeted delivery system capable of shuttling siRNAs into breast cancer cells, resulting in suppression of HER2-positive tumor growth and metastasis with no evident toxicity.

According to Harvard Medical School's Judy Lieberman, who is one of the paper's authors and a co-developer of the technology, the results are highly promising but further development work will likely need to be conducted in collaboration with an industry partner.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.